Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 500

1.

IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer.

Zhou H, Qian W, Uckun FM, Zhou Z, Wang L, Wang A, Mao H, Yang L.

Proc SPIE Int Soc Opt Eng. 2016 Apr 17;9836. pii: 98361O. Epub 2016 May 17.

2.

Suppression of Hepatic Inflammation via Systemic siRNA Delivery by Membrane-Disruptive and Endosomolytic Helical Polypeptide Hybrid Nanoparticles.

He H, Zheng N, Song Z, Kim KH, Yao C, Zhang R, Zhang C, Huang Y, Uckun FM, Cheng J, Zhang Y, Yin L.

ACS Nano. 2016 Feb 23;10(2):1859-70. doi: 10.1021/acsnano.5b05470. Epub 2016 Jan 26.

PMID:
26811880
3.

Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL.

Uckun FM, Mitchell LG, Qazi S, Liu Y, Zheng N, Myers DE, Song Z, Ma H, Cheng J.

EBioMedicine. 2015 Apr 30;2(7):649-59. doi: 10.1016/j.ebiom.2015.04.016. eCollection 2015 Jul.

4.
5.

IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.

Zhou H, Qian W, Uckun FM, Wang L, Wang YA, Chen H, Kooby D, Yu Q, Lipowska M, Staley CA, Mao H, Yang L.

ACS Nano. 2015 Aug 25;9(8):7976-91. doi: 10.1021/acsnano.5b01288. Epub 2015 Aug 10.

7.

Targeting leukemic stem cells with multifunctional bioactive polypeptide nanoparticles.

Uckun FM, Qazi S, Cheng J.

Future Oncol. 2015;11(8):1149-52. doi: 10.2217/fon.15.31. No abstract available.

PMID:
25832872
8.

Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency.

Cai K, He X, Song Z, Yin Q, Zhang Y, Uckun FM, Jiang C, Cheng J.

J Am Chem Soc. 2015 Mar 18;137(10):3458-61. doi: 10.1021/ja513034e. Epub 2015 Mar 10.

PMID:
25741752
9.

Redox-responsive, reversibly-crosslinked thiolated cationic helical polypeptides for efficient siRNA encapsulation and delivery.

Zheng N, Song Z, Liu Y, Zhang R, Zhang R, Yao C, Uckun FM, Yin L, Cheng J.

J Control Release. 2015 May 10;205:231-9. doi: 10.1016/j.jconrel.2015.02.014. Epub 2015 Feb 13.

PMID:
25683619
10.

CD22ΔE12 as a molecular target for RNAi therapy.

Uckun FM, Ma H, Cheng J, Myers DE, Qazi S.

Br J Haematol. 2015 May;169(3):401-14. doi: 10.1111/bjh.13306. Epub 2015 Feb 6.

11.

Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.

Uckun FM, Myers DE, Qazi S, Ozer Z, Rose R, D'Cruz OJ, Ma H.

J Clin Invest. 2015 Mar 2;125(3):1006-18. doi: 10.1172/JCI76610. Epub 2015 Jan 26.

12.

A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies.

Uckun FM, Qazi S, Ma H, Yin L, Cheng J.

EBioMedicine. 2014 Dec;1(2-3):141-155.

13.

CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.

Uckun FM, Qazi S, Ma H, Reaman GH, Mitchell LG.

Integr Biol (Camb). 2015 Feb;7(2):237-49. doi: 10.1039/c4ib00221k.

14.
15.

CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.

Myers DE, Yiv S, Qazi S, Ma H, Cely I, Shahidzadeh A, Arellano M, Finestone E, Gaynon PS, Termuhlen A, Cheng J, Uckun FM.

Integr Biol (Camb). 2014 Aug;6(8):766-80. doi: 10.1039/c4ib00095a.

16.
17.

Vaginal microbicides and their delivery platforms.

D'Cruz OJ, Uckun FM.

Expert Opin Drug Deliv. 2014 May;11(5):723-40. doi: 10.1517/17425247.2014.888055. Epub 2014 Feb 8. Review.

PMID:
24506783
18.
19.

KU HAPLOINSUFFIENCY CAUSES A LYMPHOPROLIFERATIVE DISORDER OF IMMATURE T-CELL PRECURSORS DUE TO IKAROS MALFUNCTION.

Ozer Z, Qazi S, Ishkhanian R, Hasty P, Ma H, Uckun FM.

Int J Mol Med Sci. 2013 Jun 21;3(7):50-64.

21.

Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients.

Uckun FM, Ma H, Ishkhanian R, Arellano M, Shahidzadeh A, Termuhlen A, Gaynon PS, Qazi S.

PLoS One. 2013 Nov 20;8(11):e80732. doi: 10.1371/journal.pone.0080732. eCollection 2013.

22.

Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase.

Ma H, Qazi S, Ozer Z, Zhang J, Ishkhanian R, Uckun FM.

PLoS One. 2013 Aug 19;8(8):e71302. doi: 10.1371/journal.pone.0071302. eCollection 2013.

23.

Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.

Cely I, Yiv S, Yin Q, Shahidzadeh A, Tang L, Cheng J, Uckun FM.

J Anal Oncol. 2012 Jun 25;1(1):1-9.

24.

Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation.

Yin L, Song Z, Qu Q, Kim KH, Zheng N, Yao C, Chaudhury I, Tang H, Gabrielson NP, Uckun FM, Cheng J.

Angew Chem Int Ed Engl. 2013 May 27;52(22):5757-61. doi: 10.1002/anie.201209991. Epub 2013 Apr 22. No abstract available.

25.

Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia.

Uckun FM, Qazi S, Cely I, Sahin K, Shahidzadeh A, Ozercan I, Yin Q, Gaynon P, Termuhlen A, Cheng J, Yiv S.

Blood. 2013 May 23;121(21):4348-54. doi: 10.1182/blood-2012-11-470633. Epub 2013 Apr 8.

26.

Protein kinase inhibitors against malignant lymphoma.

D'Cruz OJ, Uckun FM.

Expert Opin Pharmacother. 2013 Apr;14(6):707-21. doi: 10.1517/14656566.2013.780031. Review.

27.

Novel Bruton's tyrosine kinase inhibitors currently in development.

D'Cruz OJ, Uckun FM.

Onco Targets Ther. 2013;6:161-76. doi: 10.2147/OTT.S33732. Epub 2013 Mar 6.

28.

Biotargeted nanomedicines for cancer: six tenets before you begin.

Goldberg MS, Hook SS, Wang AZ, Bulte JW, Patri AK, Uckun FM, Cryns VL, Hanes J, Akin D, Hall JB, Gharkholo N, Mumper RJ.

Nanomedicine (Lond). 2013 Feb;8(2):299-308. doi: 10.2217/nnm.13.3.

29.

Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoconjugates.

Tang L, Gabrielson NP, Uckun FM, Fan TM, Cheng J.

Mol Pharm. 2013 Mar 4;10(3):883-92. doi: 10.1021/mp300684a. Epub 2013 Feb 12.

30.

Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros.

Uckun FM, Ma H, Zhang J, Ozer Z, Dovat S, Mao C, Ishkhanian R, Goodman P, Qazi S.

Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18072-7. doi: 10.1073/pnas.1209828109. Epub 2012 Oct 15.

31.

Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.

Uckun FM, Qazi S, Dibirdik I, Myers DE.

Integr Biol (Camb). 2013 Jan;5(1):122-32. doi: 10.1039/c2ib20114c.

PMID:
22990208
32.

Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS.

Uckun FM, Cahn P, Qazi S, D'Cruz O.

Expert Opin Investig Drugs. 2012 Apr;21(4):489-500. doi: 10.1517/13543784.2012.664635. Epub 2012 Feb 24. Review.

PMID:
22360744
33.

A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea]).

D'Cruz OJ, Qazi S, Yiv S, Uckun FM.

Expert Opin Investig Drugs. 2012 Mar;21(3):265-79. doi: 10.1517/13543784.2012.655422. Epub 2012 Feb 1. Review.

PMID:
22292483
34.

CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.

Ma H, Qazi S, Ozer Z, Gaynon P, Reaman GH, Uckun FM.

Br J Haematol. 2012 Jan;156(1):89-98. doi: 10.1111/j.1365-2141.2011.08901.x. Epub 2011 Oct 21.

PMID:
22017452
35.

Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network.

Uckun FM, Qazi S, Ozer Z, Garner AL, Pitt J, Ma H, Janda KD.

Br J Haematol. 2011 Jun;153(6):741-52. doi: 10.1111/j.1365-2141.2011.08671.x. Epub 2011 Apr 25.

PMID:
21517817
36.

Recombinant human CD19-ligand protein as a potent anti-leukaemic agent.

Uckun FM, Sun L, Qazi S, Ma H, Ozer Z.

Br J Haematol. 2011 Apr;153(1):15-23. doi: 10.1111/j.1365-2141.2011.08583.x. Epub 2011 Feb 17.

PMID:
21323891
37.

JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.

Uckun FM, Pitt J, Qazi S.

Expert Rev Anticancer Ther. 2011 Jan;11(1):37-48. doi: 10.1586/era.10.203. Epub 2010 Nov 11. Review.

PMID:
21070101
38.

Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor.

Uckun FM, Dibirdik I.

Nutr Cancer. 2010;62(7):968-72. doi: 10.1080/01635581.2010.513471.

PMID:
20924972
39.

CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Uckun FM, Goodman P, Ma H, Dibirdik I, Qazi S.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16852-7. doi: 10.1073/pnas.1007896107. Epub 2010 Sep 14.

40.

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.

Uckun FM, Qazi S.

Expert Rev Anticancer Ther. 2010 Sep;10(9):1407-18. doi: 10.1586/era.10.112. Review.

PMID:
20836676
41.

Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.

Uckun FM, Qazi S.

Expert Opin Ther Pat. 2010 Nov;20(11):1457-70. doi: 10.1517/13543776.2010.517750. Epub 2010 Sep 10. Review.

PMID:
20831363
42.

Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK).

Uckun FM, Dibirdik I, Qazi S.

Radiat Res. 2010 Oct;174(4):526-31. doi: 10.1667/RR2246.1.

PMID:
20731589
43.
44.

Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.

Uckun FM, Dibirdik I, Qazi S, Yiv S.

Arzneimittelforschung. 2010;60(4):210-7. doi: 10.1055/s-0031-1296275. Erratum in: Arzneimittelforschung. 2010;60(5):286.

PMID:
20486472
45.

Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets.

Qazi S, Uckun FM.

Br J Haematol. 2010 Jun;149(6):865-73. doi: 10.1111/j.1365-2141.2010.08177.x. Epub 2010 Apr 4.

PMID:
20377589
46.

Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.

Uckun FM, Ek RO, Jan ST, Chen CL, Qazi S.

Br J Haematol. 2010 May;149(4):508-17. doi: 10.1111/j.1365-2141.2010.08106.x. Epub 2010 Feb 11.

PMID:
20151979
47.

STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.

Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2902-7. doi: 10.1073/pnas.0909086107. Epub 2010 Jan 29.

48.

Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress.

Uckun FM, Ozer Z, Qazi S, Tuel-Ahlgren L, Mao C.

Br J Haematol. 2010 Mar;148(5):714-25. doi: 10.1111/j.1365-2141.2009.07983.x. Epub 2009 Nov 12.

PMID:
19912216
49.

Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Trigg ME, Sather HN, Reaman GH, Tubergen DG, Steinherz PG, Gaynon PS, Uckun FM, Hammond GD; Children's Oncology Group.

Leuk Lymphoma. 2008 Jun;49(6):1142-54. doi: 10.1080/10428190802074593.

PMID:
18569638
50.

Clinical potential of targeting Bruton's tyrosine kinase.

Uckun FM.

Int Rev Immunol. 2008 Jan-Apr;27(1-2):43-69. doi: 10.1080/08830180701784588. Review.

PMID:
18300055

Supplemental Content

Loading ...
Support Center